In the Asia-Pacific pharmaceutical industry, there were 123 M&A deals announced in Q3 2024, worth a total value of $8.1bn, according to GlobalData’s Deals Database. The $1.6bn acquisition of Bharat Serums And Vaccines by Mankind Pharma was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Asia-Pacific increased by 200% in Q3 2024 compared with the previous quarter’s total of $2.7bn and rose by 79% as compared to Q3 2023. Related deal volume increased by 32% in Q3 2024 versus the previous quarter and was 21% higher than in Q3 2023.
The top-ranked financial advisors supporting these M&A deals in Asia-Pacific in 9M 2024 were BDA Partners; KPMG International Coop; UBS Group with 5, 4, 4 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Asia-Pacific in 9M 2024 were Khaitan & Co; AZB & Partners; A&O Shearman with 6, 4, 3 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.